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Currently there are three targeted therapies approved 
for the treatment of colorectal cancers. These include 
the epidermal growth factor receptor (EGFR) inhibitors, 
cetuximab and panitumumab, and the multikinase inhibitor 
regorafenib. It is important to understand and recognize 
the common presentations of cutaneous toxicity that result 
from these agents to effectively manage symptoms and 
prevent premature discontinuation of anticancer treatment.
EGFR inhibitors
Cetuximab and panitumumab are intravenous monoclonal 
antibody EGFR inhibitors. Cetuximab was first FDA-
approved in 2004 for metastatic colorectal carcinoma and 
in 2012, it was approved as first-line treatment of KRAS 
mutant-negative, EGFR-expressing metastatic colorectal 
cancer. Panitumumab was first FDA-approved in 2006 for 
the treatment of EGFR-expressing metastatic colorectal 
cancer.
The most common cutaneous toxicity resulting from 
treatment with EGFR inhibitors is the development of 
an acneiform eruption. This consists of follicular sterile 
pustules and papules usually involving the face, scalp, 
and upper trunk (Figures 1,2,3). Secondary infections are 
commonly observed, but must be confirmed by bacterial 
culture. Histopathology shows folliculitis with collections 
of neutrophils within the follicles and lymphocytes 
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Figure 1 Acneiform rash affecting the face during EGFR inhibitor 
treatment
surrounding the follicles. It is essential to understand that 
this eruption resembles acne (hence the term “acneiform”), 
but is actually not acne. This eruption lacks comedones 
and does not respond to topical retinoids, both of which 
are cornerstones of traditional acne vulgaris. The basic 
differential diagnosis for the acneiform eruption induced 
by EGFR inhibitors includes steroid induced acne and 
infectious folliculitis caused by bacteria or yeast. Positive 
correlations between the development of acneiform 
eruptions and clinical outcomes have been observed so it 
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is important to treat through these reactions and reserve 
discontinuation of medication as a last resort. 
The Common Terminology Criteria for Adverse Events 
established by the National Cancer Institute defines the 
severity of acneiform rash from grades one through five as 
shown in Table 1. 
Studies have been conducted to explore the pathogenesis 
of the acneiform eruption caused by EGFR inhibitors. 
The EGF receptor is present in keratinocytes in the 
basal and suprabasal layers of the epidermis and the outer 
layers of hair follicles. Stimulation of the EGFR pathway 
promotes keratinocyte survival and proliferation. Han 
et al. found increased expression of cytokines such as 
interleukin-1 alpha, tumor necrosis factor-alpha, and 
interferon-gamma in acneiform lesions of patients when 
EGFR was inhibited by cetuximab. These increased 
cytokines may lead to inflammation in the dermis. This 
inflammation is characterized by neutrophilic inflammatory 
infiltrates followed by follicular proliferation and plugging 
that causes the papulopustular eruption. The mechanism 
is distinct from the etiology of acne vulgaris, where 
inflammation follows comedone formation. This explains 
why topical steroids are an effective treatment for the severe 
papulopustular eruption caused by cetuximab but may 
worsen acne vulgaris. 
Most patients receiving cetuximab or panitumumab 
(up to 90%) will develop the acneiform eruption within 
the first two weeks of therapy (2,3). Tol et al. reported a 
phase III study comparing toxicity of adding cetuximab to 
a combination treatment with capecitabine, oxaliplatin and 
bevacizumab (4). In the cohort not taking cetuximab only 
7 of 197 experienced an acneiform skin rash. In the 
cetuximab group 156 of 197 developed an acneiform skin 
rash with fifty of these patients categorized as grades 3 or 
4 severity. Patients on panitumumab have an increased 
incidence of acneiform eruptions but similar clinical findings 
when compared to the cutaneous toxicities induced by 
cetuximab. Douillard et al. reported results of a phase III trial 
of panitumumab with infusional fluorouracil, leucovorin, 
and oxaliplatin (FOLFOX4) versus FOLFOX4 alone (5). 
In the 545 patients treated with FOLFOX4 alone only 
ten developed skin toxicity. Of patients treated with 
panitumumab plus FOLFOX4 182 of 539 developed skin 
toxicity. 
Perez-Soler and Saltz were the first to report the 
association of acneiform rash due to EGFR inhibitors as a 
Figure 2 Acneiform rash affecting the back during EGFR inhibitor 
treatment
Figure 3 Acneiform rash affecting the chest during EGFR 
inhibitor treatment
Table 1 Common Terminology Criteria for Adverse Events-Acneiform rash





BSA; +/- pruritis or 
tenderness
Papules/pustules  
covering 10-30% BSA; 
psychosocial impact & 
limiting instrumental  
activities of daily living
Papules/pustules covering >30% 
BSA; limiting self care activities  
of daily living; associated with  
local superinfections with oral 
antibiotics indicated
Papules/pustules covering any 
percentage BSA; extensive  
superinfection with intravenous 
antibiotics indicated;  
life-threatening consequences
Death
Reproduced from the Common Terminology Criteria for Adverse Events version 4.0. (http://www.cancer.gov) (1)
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surrogate marker for efficacy in 2005 (6). This association 
only holds true for the acneiform rash due to EGFR 
inhibitors. Other forms of EGFR inhibitor cutaneous 
toxicity such as paronychia, hair and nail changes, and 
xerosis discussed later are not considered markers for 
efficacy. Multiple studies suggest that a positive correlation 
exists between occurrence of an acneiform rash and both 
the cancer’s response to the EGFR-targeted therapy and 
patient survival. Since cutaneous toxicity may be associated 
with improved clinical outcomes, it is important to avoid 
stopping EGFR inhibitor treatments for cutaneous toxicities 
and, instead, treat through eruptions. To better counsel 
patients about the risks of the cutaneous toxicities of EGFR 
inhibitors, Jatoi et al. evaluated whether any patients have 
died from rashes caused by EGFR inhibitors (7). After 
reviewing 117 trials including 8,998 cancer patients where 
the rate of rash development was greater than 50%, they 
concluded that there were no reported rash-related deaths.
In addition to the physical effects of EGFR inhibitors, 
several researchers addressed the psychological and 
emotional effects of cutaneous toxicity. Romito et al. 
studied the psychological effect of the cutaneous skin rash 
in eighty advanced colorectal cancer patients treated with 
cetuximab (8). Forty-one percent reported psychological 
distress caused by the rash. When questioned about how 
the rash affected the willingness of patients to go out into 
public, 22% “very much” avoided going out and 25% 
“somewhat” avoided going out. In addition to the cosmetic 
effects, a significant psychological and quality of life effect 
from these eruptions results from physical symptoms of 
burning, stinging, and itching (9). It is, therefore, clear that 
treating the cutaneous toxicities of EGFR inhibitors not 
only allows patients to continue on potentially life saving 
oncology treatments but also can greatly improve their 
quality of life.
Several authors have reviewed treatments of the 
cutaneous toxicity associated with EGFR inhibitor 
receptors. Jatoi et al. conducted a randomized, double-
blinded placebo controlled study with 65 patients 
comparing tetracycline 500 mg orally twice per day for 
28 days versus placebo (10). Monitoring was done for 
the four weeks of treatment and an additional four weeks 
with primary objective to compare incidence of grade 2 or 
worse rash between the groups. This study found that oral 
tetracycline did not significantly lessen rash incidence or 
severity in patients taking EGFR inhibitors. Scope et al. 
conducted a randomized double-blind controlled trial of 
oral minocycline for cetuximab induced acneiform eruption 
published in 2007 (11). Of 48 patients enrolled, half were 
randomly assigned to minocycline and the other half to 
placebo for 8 weeks of treatment. Total facial lesion counts 
were significantly lower for patients receiving treatment 
rather than placebo at week one through four. At week four 
patients in the minocycline treatment group had a lower 
frequency of moderate to severe rash than patients receiving 
placebo and at week eight there were diminished total 
facial lesion counts. No patients treated with minocycline 
had to discontinue cetuximab treatment due to acneiform 
eruption but four patients in the placebo group had to 
interrupt treatment because of grade 3 skin rash. Topical 
tazarotene use was also studied. Tazarotene was not helpful 
in controlling the acneiform rash and caused significant 
irritation, supporting the observation that this condition 
does not respond like traditional acne vulgaris. 
 De Noronha et al. reviewed the management of 
cutaneous side effects during erlotinib and cetuximab 
treatment in lung and colorectal cancer patients (12). They 
presented a treatment algorithm to help manage these 
patients. Upon initiation of treatment with the EGFR 
inhibitor they started patients on daily sunscreen, mild skin 
cleanser, and moisturizing cream. In patients who developed 
mild acneiform eruptions they began topical antibiotics plus 
topical benzoyl peroxide. For patients who developed grade 
2 or 3 cutaneous reactions they started oral doxycycline 
or minocycline at a dose of 100 mg/day. In one case that 
was not responsive to oral antibiotics they initiated oral 
low dose isotretinoin. Antihistamines were recommended 
when patients experienced pruritis. In the nineteen cases 
described by these authors none had to stop EGFR 
inhibitor treatment because of cutaneous side effects, all but 
one patient showed improvement on oral antibiotics, and 
42% experienced a complete response.
The skin toxicity evaluation protocol with panitumumab 
(STEPP) study conducted by Lacouture et al. was a 
randomized trial evaluating pre-emptive versus reactive 
treatment with doxycycline for patients receiving 
panitumumab (13). All patients started a standard regimen 
of daily skin moisturizer, sunscreen, and topical steroid 
at the onset of chemotherapy. Forty-eight patients also 
received pre-emptive treatment with doxycycline 100 mg 
twice per day, while forty-seven received doxycycline 
only after skin toxicity developed. The incidence of grade 
2 skin toxicities during the six-week treatment period was 
29% for the pre-emptive treatment group and 62% for the 
reactive treatment group. The pre-emptive treatment with 
doxycycline was well tolerated and patients in this group 
reported less impairment of quality of life.
Requena et al. reported three cases of severe acneiform 
eruptions induced by EGFR inhibitors that were 
successfully treated to the point of complete response with 
oral isotretinoin (14). In data pending publication, we 
have also had success with over a dozen patients using oral 
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isotretinoin to successfully treat cases of severe acneiform 
eruptions caused by EGFR inhibitors (15).
Other cutaneous toxicities can be observed during 
treatment with EGFR inhibitors. Patients may develop 
xerosis and painful fissuring (Figure 4). As described by Han 
et al. EGFR inhibitor use leads to abnormal differentiation 
of keratinocytes with decreased levels of filaggrin and 
loricrin (16). These are both components of the outer skin 
layer known as the stratum corneum and play a role in the 
retention of moisture. Decreased levels of these proteins 
may explain the xerosis observed in the cutaneous EGFR 
induced drug rashes. Rodríguez-Murphy et al. studied a 
group of forty-three patients treated with cetuximab and 
observed xerosis in less than a quarter of patients after a 
mean delay of 40 days (17). Three patients in this group 
developed painful fissures on the hands and feet. Xerosis is 
actually much more common though and likely the follow-
up in this study was not adequate for assessment. In 2009, 
Osio et al. reported a study describing the cutaneous side-
effects in sixteen patients on long-term treatment with 
epidermal growth factor receptor inhibitors with the range 
of follow-up from 6 to 27 months and mean treatment 
10 months and found xerosis present in all patients (18). All 
patients should be counseled on dry skin care prevention 
with lukewarm showers or baths, minimal soap usage 
(primarily axilla, groin, and feet), and thick emollient 
usage daily. Fissures are best treated with super glue for 
immediate closure.
Patients on EGFR inhibitors may develop nailfold 
changes after two or more months of treatment. These 
most commonly include nailfold inflammation (paronychia) 
and periungual pyogenic granuloma-like lesions (Figure 5). 
As a secondary processes resulting from nail matrix 
inflammation, the nails can become dystrophic or the nail 
plates may lift from the nail beds (onycholysis). Trauma 
is not required to precede the changes but is likely an 
aggravating factor. Both fingernails and toenails can be 
affected and the first digits are most commonly affected. 
The affected digits are painful and morbidity may be high 
due to impaired functionality limiting activities of daily 
living. Rodríguez-Murphy et al. studied a group of forty-
three patients treated with cetuximab and found that two 
developed paronychia (17). 
Although paronychia is often sterile, lesions may become 
superinfected so culturing the lesion is recommended 
for appropriate antimicrobial selection and treatment. 
Lacouture et al. described a retrospective study of 
152 patients treated with cetuximab in which 27 cases 
of paronychia developed for an incidence of 17.7% (19). 
Forty-two culture swabs were performed and all cultures 
grew some organisms. Nosocomial colonization with 
coagulase-negative gram-positive bacteria was found in 
31% and Staphylococcus aureus infection was found in 
23%. Recommendations for minimizing periungual trauma 
include comfortable shoes, keeping nails trimmed but 
avoiding aggressive manicuring, and wearing gloves for 
protection while cleaning and doing housework. Topical 
corticosteroids and anti-inflammatory doses of tetracyclines 
may help decrease periungual inflammation while 
antimicrobial soaks such as dilute bleach in water or dilute 
white vinegar in water can prevent superinfection.
The periungual pyogenic granuloma-like lesions 
clinically appear as friable vascular tissue overgrowth and 
commonly bleed. Local trauma may precede development of 
the lesions or aggravate them leading to increased symptoms 
of bleeding. Santiago et al. studied fourteen patients on 
EGFR inhibitors cetuximib or erlotinib and observed that 
five patients developed periungual pyogenic granulomas 
and four of these patients also had paronychia (20). 
The pyogenic granulomas occurred an average of eight 
Figure 4 Fissure on finger developed during EGFR inhibitor 
treatment
Figure 5 Paronychia with periungual pyogenic granuloma-like 
lesions associated with EGFR inhibitor treatment
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weeks after beginning treatment. Medical intervention may 
be necessary to eliminate excessive granulation tissue and 
treatment options include electrocautery, silver nitrate, and 
nail avulsion.
Abnormalities of the hair can develop in patients taking 
EGFR inhibitors. Patients may experience hypertrichosis 
or increased hair growth. Specifically, increased hair growth 
of the eyebrows and eyelashes (trichomegaly) may occur 
(Figure 6). Patients can also develop scalp alopecia, which 
may be scarring or nonscarring.
Cutaneous superinfections can complicate the cutaneous 
toxicities affecting patients treated with EGFR inhibitors 
(Figure 7). Several studies have been conducted to explore 
the microbiology of these infections. Amitay-Laish et al. 
studied 29 patients on EGFR inhibitors cetuximab or 
erlotinib and found that 24 patients had a papulopustular 
reaction (21). They divided this cohort into two groups 
based on when they developed the papulopustular eruption. 
The early phase group contained seventeen patients and 
had a median onset at 8 days. The late phase group had 
a median onset at 200 days and contained seven patients. 
Staphylococcus aureus was found in 7 of 13 early phase 
patients and in all 7 late phase patients. The high incidence 
of staphylococcal infection demonstrates the importance 
of bacterial cultures in the assessment and treatment of 
EFGR inhibitor eruptions. This study also emphasizes the 
importance of seeking a pathogenic microbial cause when 
patients who were stable on the EGFR inhibitors develop 
a late onset papulopustular reaction. Eilers et al. studied 
221 patients treated with EGFR inhibitors and found 
that 84 showed evidence of infection at the sites of the 
cutaneous toxicity (22). Cultures revealed that fifty were 
Figure 6 Trichomegaly during EGFR inhibitor treatment
Figure 7 Cutaneous bacterial superinfection during EGFR 
inhibitor treatment
positive for Staphylococcus aureus and twelve were positive 
for methicillin-resistant Staphylococcus aureus. Other less 
common infections included herpes simplex, herpes zoster, 
and dermatophytes. Occasionally uncommon pathogens 
can be identified in patients taking EGFR inhibitors, 
as demonstrated by Bark et al. who reported a case of 
disseminated cutaneous Mycobacterium chelonae in a 
patient with head and neck cancer on salvage chemotherapy 
with cetuximab (23). This reinforces the value of bacterial 
cultures to determine specific pathogenic agents in cases 
that are not responding to typical treatment regimens. 
Our treatment algorithm begins with examining 
patients in clinic either before or soon after starting 
EGFR inhibitors but preceding the development of 
significant cutaneous toxicity. Patients are instructed 
to use sunscreen and dry skin care is reviewed with an 
emphasis placed on using emollients such as Vaseline 
or thick body creams regularly. Topical steroids can 
be prescribed such as triamcinolone 0.1% cream or 
ointment for use once to twice per day as needed for 
itchy scaly red rashes. Oral antibiotics are started when 
chemotherapy is initiated, prior to rash development, 
to prevent or minimize the acneiform eruption. The 
usual treatment consists of minocycline 50 or 100 mg 
twice per day and side effects such as headache, dizziness, 
hypersensitivity reaction, and drug-induced rash are 
reviewed. Patients are instructed to stop the medication 
immediately if a new rash or other side effect develops. 
Another option for treatment is doxycycline 50 or 100 mg 
twice per day and side effects of gastrointestinal upset and 
photosensitivity are reviewed. Patients are instructed to 
take the pills with food and a full glass of water to limit 
the gastrointestinal side effects. When lesions persist 
or worsen despite treatment with oral antibiotics and 
topical steroids it may helpful to rule out superinfection. 
When infection is absent in the setting of a difficult to 
manage acneiform eruption, the practitioner should 
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start oral isotretinoin. If the practitioner is uncomfortable 
prescribing or managing treatment with oral isotretinoin, 
referral to a dermatologist with knowledge of EGFR 
inhibitor induced cutaneous toxicities may be beneficial 
for the initiation of treatment.
Regorafenib
The newest targeted therapy approved for the treatment of 
colorectal cancers is the multikinase-inhibitor regorafenib. 
Regorafenib is an oral multikinase inhibitor that targets 
vascular endothelial growth factor receptor 2, platelet-
derived growth factor receptor-β, fibroblast growth factor 
receptor 1, C-KIT, RET, and B-RAF (24). Regorafenib is 
currently being studied for use in gastrointestinal stromal 
tumors (GIST), colorectal carcinoma, and renal cell 
carcinoma. While similar to older multikinase inhibitors 
such as sorafenib and sunitinib, regorafenib also has 
structurally and biologically unique properties allowing for 
its use when tumors become resistant to these older agents. 
Phase III clinical trials of regorafenib in gastrointestinal 
stromal tumors that developed resistance to imatinib 
and sunitinib have shown increased medial progression 
free survival compared to placebo (25). Similarly, in 
colorectal cancer median overall survival was 6.4 months 
in the regorafenib group versus 5 months in the placebo 
group (26). We will review the side effects of similar 
multikinase-inhibitors, sorafenib and sunitinib, and present 
what is known to date to occur from Regorafenib. Sorafenib 
targets B-RAF, VEGF-2, C-KIT, fetal liver TK(Flt)-3, 
and PDGFR. It is associated with hand-foot skin reaction 
(HFSR) and splinter hemorrhages as well as a seborrhea-like 
facial rash and a follicular rash on the trunk and extremities. 
Sunitinib targets VEGF-2, C-KIT, Flt-3, and PDGFR. 
It is associated with HFSR and splinter hemorrhages plus 
hair depigmentation, skin discoloration, and neutrophilic 
dermatoses.
HFSR can occur with regorafenib, and has long been a 
known side effect of multikinase inhibitors such as sorafenib 
and sunitinib. HFSR from multikinase inhibitors is a unique 
cutaneous toxicity pattern that should be distinguished 
from acral erythema (also known as hand foot syndrome 
and palmoplantar dysthesthesia) seen with classic cytotoxic 
chemotherapy. Patients with HFSR from multikinase 
inhibitors experience acral pain and dysesthesia, but usually 
to a lesser extent and with less edema than when caused by 
chemotherapy agents such as 5-flourouracil, doxorubicin, 
and cytosine arabinoside. The most characteristic feature 
of HFSR is the development of palmar and plantar 
hyperkeratotic plaques (Figures 8,9). These occur most often 
over areas of friction. During treatment with sorafenib and 
sunitinib, high grade hand-foot skin reactions have been 
reported to occur in up to 9% of cases resulting in impaired 
functionality from blisters and ulceration (27). Nardone 
et al. found these drug induced hand-foot skin reactions 
negatively impacted the patients’ health-related quality of 
life scores (28). 
Hand and foot skin reactions are known to occur 
in patients receiving regorafenib for the treatment of 
metastatic adenocarcinoma of the colon. Often several 
weeks after starting the medication painful blistering plaques 
or rash develop on the feet and tender thickened plaques 
may develop on fingertips. This rash may affect activities 
of daily living because of the blistering, thickening, and 
discomfort that is frequently most severe at pressure points 
such as balls of the feet and fingertips. In clinical trials 
treating gastrointestinal stromal tumors with regorafenib, 
Demetri et al. reported that 20% of patients (26 of 132) 
Figure 8 Hyperkeratotic plaques on areas of friction from 
regorafenib Figure 9 Hyperkeratotic plaque on thumb from regorafenib
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developed a hand-foot skin reaction (25). In clinical trials 
treating colorectal cancer with regorafenib, Grothey et al. 
observed grade three or higher hand-foot skin reactions in 
17% of patients (83 of 500) (26).
Management of the HFSR can be challenging but the 
basic principles include minimizing friction and trauma 
with comfortable well fitting shoes and protective gloves. 
Topical corticosteroids can minimize inflammation and 
thickened hyperkeratotic plaques on the hands and feet can 
be softened with the use of keratolytic creams such as urea 
or lactic acid. Dose reduction of the regorafenib is another 
option for reducing the bothersome side effects. Unlike 
with the acneiform eruption seen with EFGR inhibitors, 
Figure 10 Seborrheic dermatitis-like rash developed during 
regorafenib treatment
Figure 12 Development of squamous cell carcinoma during 
treatment with vemurafenib (BRAF-inhibitor)
Figure 11 Follicular keratotic papules associated with multikinase-
inhibitor treatment
there is no known correlation of the HFSR rash or any 
other cutaneous toxicity from regorafenib to efficacy of the 
medication. 
A seborrheic dermatitis-like rash may occur while taking 
multikinase inhibitors, including regorafenib (Figure 10). 
The seborrhea-like facial rash can typically be controlled 
with topical medications. Low potency corticosteroids such 
as hydrocortisone 2.5% cream or ketoconazole cream may 
be beneficial. 
A follicular rash may develop during treatment with 
multikinase inhibitors as described by Lopez et al. (29). 
Clinically this manifests as skin colored to erythematous 
follicular keratotic papules (Figure 11). Histopathology 
shows prominent  fo l l icular  hyperplas ia .  Topica l 
corticosteroids or topical keratolytics may be helpful for 
symptomatic control. 
Cutaneous  squamous  ce l l  c a rc inoma  and  the 
inflammation of actinic keratoses were reported to be 
associated with sorafenib in 2009 by Dubauskas et al. (30). 
In 131 patients treated with sorafenib for metastatic 
renal cell carcinoma, seven cases of cutaneous squamous 
cell carcinoma and two cases of keratoacanthoma type 
squamous cell carcinoma were reported. In 2013, Breaker 
et al. reported an association with skin cancer and the use 
of sorafenib and sunitinib for renal cell carcinoma (31). 
Of 69 patients treated with multikinase inhibitors, five 
patients on sorafenib and two patients on sunitinib 
developed skin cancers, of which five lesions were 
squamous cell carcinomas and three lesions were basal 
cell carcinomas. The median treatment durations before 
identification of the skin cancer was longer than one year. 
Figure 12 shows a squamous cell carcinoma that developed 
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during treatment with a multikinase-inhibitor. The BRAF 
inhibitor vemurafenib is used in the treatment of metastatic 
melanoma. Vemurafenib also triggers the development of 
squamous cell carcinomas possibly through the activation of 
wild-type RAF in sun-damaged keratinocytes. Long-term 
follow-up of regorafenib treatment will be necessary to 
determine if similar cutaneous skin cancer risks exist.
These findings highlight how familiarity with the 
characteristic skin reactions observed in classes or families 
of targeted chemotherapeutics may help predict what 
reactions to expect from new agents. Knowledge of the 
presentation and treatment of the cutaneous toxicities 
caused by targeted therapies approved for the treatment of 
colorectal cancers is extremely important for the practicing 
oncologist and dermatologist. Successful treatment 
improves patients’ quality of life while undergoing these 
therapies. It addition, by minimizing the cutaneous side 
effects patients experience these life-saving treatments can 
be continued at the proper doses and durations to allow for 
the most effective treatment of their cancers.
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